Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of brexpiprazole adjunctive treatment in major depressive disorder
2012-004169-42Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoint: Safety and tolerability of brexpiprazole adjunctive treatment. Started Jun 2013; status: terminated.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2012-004169-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004169-42.